REQUEST AN APPOINTMENT

Adjuvant Therapies for Fertility

At CIS, we recognise that fertility is more than a medical diagnosis — it is a deeply personal journey that may benefit from a supportive and integrative approach.

In conjunction with standard fertility treatment, some individuals choose to explore adjuvant or complementary therapies aimed at supporting general wellbeing and reproductive health. These options are discussed within an evidence-informed, multidisciplinary framework and always in consultation with qualified health professionals.

These therapies are not replacements for medical fertility treatment. Rather, they may be considered as adjunctive measures to complement ongoing medical care and are incorporated only when deemed appropriate by your treating specialist.

Adjuvant Therapies

Fertility Support and Adjuvant Therapies

At the Centre for Infertility Solutions (CIS), fertility care is approached with the whole person in mind.

Alongside standard fertility treatments, some individuals may consider additional supportive therapies intended to assist in maintaining general wellbeing.
 All recommendations are made within an integrative, evidence-informed framework and under appropriate medical supervision.

The LOLA Protocol, developed by Dr Nick Lolatgis, is a structured clinical framework designed to investigate immune and autoimmune factors that may be relevant to fertility care.
 This approach combines diagnostic testing with specialist medical supervision, and is tailored to each patient’s individual clinical presentation.

Natural Killer (NK) Cells and Immune Function

The protocol may include assessment of Natural Killer (NK) cell activity, which forms part of the body’s normal immune defence.
 Research in this area is ongoing, and while some studies suggest that variations in NK cell activity or cytokine levels may be associated with implantation challenges, the clinical significance remains uncertain.

Evaluating these markers allows the clinical team to consider whether immune-modulating strategies could be appropriate within a comprehensive fertility care plan.

Autoimmune and Inflammatory Investigations

Further assessment may include testing for autoimmune or inflammatory markers, such as:

  • Antinuclear antibodies (ANA)

     

  • Thyroid antibodies

     

  • Antiphospholipid antibodies

     

  • Cytokine and inflammatory profiles

     

Where clinically indicated, and only under prescription, medications such as low-dose corticosteroids, aspirin, or other immunomodulatory agents may be used to help regulate identified immune activity.
 All such treatments are provided strictly under specialist supervision and always in conjunction with standard fertility care.

Important Information

The LOLA Protocol provides a structured, medically supervised framework for investigating and managing complex immune factors that may be relevant to reproduction.
 It is not intended to diagnose, treat, or cure infertility, and individual responses vary.
 Any treatment decisions are made following a thorough clinical assessment, discussion of risks and alternatives, and informed patient consent.

Lymphocyte Membrane Immunotherapy (LMIT): patient information

At a glance:

Lymphocyte Membrane Immunotherapy (LMIT) is an emerging, specialist-directed fertility therapy that focuses on the interaction between the immune system and early implantation (sometimes called allo-immunity). It is not part of standard treatment protocols in Australia. At The Infusion Centre, LMIT is available only with a written referral from your qualified fertility specialist and is provided within a nurse-led clinical setting.
 

What LMIT is (plain English)

  • LMIT is a procedure used by some fertility specialists to explore the immune aspect of implantation.
  • It aims to present selected immune signals to the body in a controlled way, under medical guidance.
  • Because research is evolving, LMIT is considered investigational. Effectiveness can vary and is not guaranteed.

Who might discuss LMIT

Your fertility specialist may raise LMIT in selected circumstances—for example, when immune factors are being explored as one possible contributor to repeated implantation problems. LMIT is not routine and is not suitable for everyone.

Intralipid is a sterile fat emulsion originally developed for hospital nutritional support. In fertility care, it has been studied for potential immune-modulating effects, though evidence for benefit in conception or pregnancy outcomes remains limited.

Any use of Intralipid should occur only under specialist supervision and after a comprehensive clinical assessment and informed consent.

Egg and sperm quality may be influenced by age, lifestyle, and overall health.

Some supplement or prescription programs — including melatonin, coenzyme Q10, L-arginine, NAD⁺ precursors, and antioxidants — are used to support general metabolic and cellular wellbeing.

There is no proven treatment to improve egg, sperm, or embryo quality, and supplement use should always be guided by a qualified practitioner familiar with the individual’s medical and reproductive profile.

Immunoglobulins are antibodies that assist in immune regulation and form part of the body’s normal defence system.
 In reproductive medicine, IVIG therapy has been studied for its potential to influence immune activity, particularly in individuals experiencing recurrent implantation failure or other immune-related reproductive challenges.

Current research findings are mixed, and there is no conclusive evidence that IVIG consistently improves fertility or pregnancy outcomes.
 Use of IVIG should occur only under specialist prescription and supervision, following a comprehensive review of medical history, diagnostic results, and potential risks and benefits.

Humira (adalimumab) is a prescription medication that targets tumour necrosis factor (TNF) — a protein involved in the body’s immune response. It is approved for use in conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

In reproductive immunology, Humira has been investigated for its potential to modulate immune activity in specific clinical contexts. Any use for reproductive purposes represents an off-label application, and its effectiveness in fertility outcomes has not been clearly established.

Use of Humira in fertility care should occur only under the prescription and supervision of a qualified specialist, following comprehensive evaluation, informed consent, and ongoing monitoring.

Uterine PRP has been investigated for its potential role in supporting endometrial lining development.

Current evidence is limited and inconclusive, and the therapy should be considered only under specialist medical supervision, following a thorough assessment and informed consent process.

Filgrastim is a synthetic form of granulocyte colony-stimulating factor (G-CSF) — a naturally occurring protein that helps regulate white blood cell production.

In reproductive medicine, it has been investigated for its potential effects on endometrial development and follicular function.

Research findings are mixed and not conclusive, and clinical outcomes can vary.

Use of Filgrastim in fertility care should occur only under the direction of a fertility specialist, following comprehensive assessment, discussion of potential risks and benefits, and informed consent.

Human Growth Hormone (HGH) is a naturally occurring protein that plays a role in growth, metabolism, and cellular function.

In reproductive medicine, HGH has 

been studied for its potential influence on follicular development, particularly in women undergoing fertility treatment.

However, the evidence supporting its benefit remains limited and inconclusive, and its use in IVF or ovarian stimulation is considered off-label.

Any decision to use HGH should be made in consultation with a reproductive endocrinologist or fertility specialist, following a comprehensive clinical assessment and informed consent process.

Stem Cell–Based Therapies

Stem Cell Oocyte Rejuvenation (SCORE)

SCORE is an experimental procedure using a patient’s own blood-derived stem cells, infused into the ovarian arteries under specialist supervision to explore potential effects on ovarian function.

There is no conclusive evidence that this therapy improves egg quality or pregnancy outcomes, and it should be considered only within an approved research or specialist clinical setting with informed consent and strict oversight.

SCUPE is an investigational procedure that involves processing a patient’s own stem cells and delivering them to the uterine arteries to study potential effects on endometrial tissue.

This therapy remains experimental, with no validated large-scale clinical evidence of benefit, and should be offered only within a specialist or research setting under strict medical supervision and informed consent.